乐普生物-B(2157.HK)中期业绩:营收5.22亿元同比增12%,中期继续盈利

格隆汇
Aug 20
乐普生物-B(2157.HK)公布中期业绩,截至2026年6月30日止六个月,公司收入约为人民币5.224亿元,同比增长约12.1%,录得正面盈利约人民币为2485万元,中期继续盈利;研发开支约为人民币2.08亿元,与去年同期基本持平。 报告期内,在国内商业化方面,集团录得销售美佑恒®(注射用维贝柯妥塔单抗)及普佑恒®(普特利单抗注射液)的收入约人民币3.713亿元,为2025年同期录得销售额的两倍以上。就许可业务而言,集团录得来自后续里程碑付款的收入约人民币1.487亿元,主要归因于CMG901及MRG007的许可交易。 截至目前,公司已在中国国内市场成功实现两款药物的商业化,多款候选药物已进入关键临床阶段,且通过联合疗法实现了治疗线数的前移。同时,公司基于自有创新技术平台持续推进新药研发,并探索新的业务开发合作机会。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10